Kodiak Sciences (NASDAQ:KOD - Get Free Report) issued its earnings results on Thursday. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.06, Zacks reports.
Kodiak Sciences Price Performance
KOD traded down $0.10 during trading on Monday, hitting $2.81. 718,531 shares of the stock traded hands, compared to its average volume of 355,720. The firm has a market capitalization of $147.87 million, a P/E ratio of -0.77 and a beta of 2.26. Kodiak Sciences has a 12-month low of $2.19 and a 12-month high of $11.60. The firm has a 50-day moving average of $4.76 and a 200 day moving average of $5.45.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on KOD. HC Wainwright reaffirmed a "neutral" rating and issued a $3.00 price objective on shares of Kodiak Sciences in a research note on Monday. Jefferies Financial Group upgraded shares of Kodiak Sciences from a "hold" rating to a "buy" rating and set a $20.00 price target for the company in a research report on Monday, December 9th.
Get Our Latest Stock Analysis on KOD
Kodiak Sciences Company Profile
(
Get Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Featured Stories
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
